1. In order to investigate the molecular mechanisms determining the hypertrophic response of the ventricular myocardium to thyroid hormone administration, changes in left and right ventricular expression of the c-myc, c-fos and H-ras proto-oncogenes in response to treatment with 3,3',5-tri-iodothyronine were defined. 2. Adult female Wistar rats were treated with daily subcutaneous injections of 3,3',5-tri-iodothyronine (50 pg) for 1, 3, 7 or 14 days (n = 6 in each treatment group) and the results from 3,3',5-tri-iodothyroninetreated animals were compared with those obtained from untreated controls ( n = 6 ) . Changes in thc weight of the left and right Ventricles in response to 3,3',5-tri-iodothyronine treatment were measured; changes in expression of the c-myc, c-fos and H-ras proto-oncogenes were determined in parallel by measurement of specific messenger RN As by Northern and dot hybridization, as well as changes in expression of fl myosin heavy chain messenger RNA.
INTRODUCTION
Cardiac hypertrophy represents an adaptive response of the ventricular myocardium to a variety of physiological and pathological stimuli which increase cardiac work. It is well known that adminstration of thyroid hormones results in cardiac hypertrophy [l] , as well as changes in functional parameters such as heart rate, cardiac output, myocardial contractility and systolic blood pressure [2, 31 . Despite these observations, the mechanisms whereby thyroid hormones induce a hypertrophic response in the myocardium remain poorly defined.
Hypertrophy induced by 3,3',5-tri-iodothyronine (T,) excess occurs because the rate of new protein synthesis exceeds the rate of degradation [4] . It is not clear whether the well-described hypertrophic response to T, reflects either a direct effect of the hormone on the myocardium or a change in cardiac work resulting from thyroid hormone administration. Direct influences of T, on myocardial gene expression have been demonstrated in vitro: we and others have reported direct effects of T, on pretranslational expression of the CI and p myosin heavy chain (MHC) genes, T, administration resulting in increased expression of CI MHC messenger RNA (mRNA) and decreased expression of p MHC mRNA [S, 61. These actions of T, on MHC mRNAs are associated with an increase in synthesis of high-ATPase V1 (.a) myosin and a decrease in synthesis of low-ATPase V3 (fib) myosin [5, 71, changes which are important determinants of myocardial oxygen consumption. Effects of thyroid hormone excess on myocardial Na+/K+-ATPase and Ca2 +-ATPase expression have also been reported [8, 91. It is clear that direct actions of T, are mediated at a cellular level by binding of the hormone to specific nuclear receptor proteins encoded by one or more c-erb A proto-oncogenes [lo] , and subsequent binding of these receptors to regulatory sequences of specific genes such as those encoding the MHC expressed in the myocardial cell [ll] . The relative importance of this direct gene regulatory effect of T, to the development of hypertrophy, compared with indirect effects mediated via changes in other signal transduction mechanisms controlling myocardial gene expression, is unclear.
The signal transduction processes involved in the hypertrophic response of the heart to pressure overload have been investigated extensively in models of left ventricular hypertrophy secondary to aortic constriction; the products of several specific protooncogenes have been implicated in mediating the hypertrophic response to such a stimulus [12] [13] [14] . The proto-oncogene products which are suggested to play a part in the growth response to pressure overload of the left ventricle (LV) include the myc and fos proteins, which are nuclear trans-acting factors, and the product of the H-ras gene, which is related to guanine nucleotide-binding proteins implicated in the coupling of growth factor signals to the inositol phosphate and adenylate cyclase intracellular second messengers [ 12, 14, 151 . Several studies have demonstrated increased levels of mRNAs encoding these proto-oncogene products within hours of induction of left ventricular pressure overload [16, 171. The hypertrophic response of the LV in such models in uiuo is also associated with a switch from synthesis of V1 to V3 myosin, reflecting increased transcription of the p MHC gene [18] , an effect which contrasts with the reduction in p MHC transcription observed after T, treatment of myocardial cells in iiitro and T, replacement of hypothyroid animals in uivo [6] .
In order to investigate the molecular mechanisms determining the hypertrophic response of the ventricular myocardium to thyroid hormone treatment, we have defined changes in expression of the c-myc, c-fos and H-ras proto-oncogenes in both the LV and right ventricle (RV) of the rat heart and have examined, in parallel, changes in expression of the fi MHC gene in both ventricles.
MATERIALS AND METHODS Animals
Adult female Wistar rats (1 8G240 g) were treated daily with subcutaneous injections of T, (50pg in 150mmol/l NaCI) for 1, 3, 7 or 14 days (n=6 in each treatment group) and the results were compared with those obtained from untreated control animals (n=6). At the end of the T, treatment period, rats were anaesthetized with ether and body weight was measured. After decapitation, hearts were removed, washed in cold phosphate-buffered saline, blotted dry, ventricles were dissected free from atria and vessels and left and right ventricular weights were determined. Ventricular tissue was frozen in liquid nitrogen immediately and stored at -70°C. The right hind leg was removed for the determination of tibial length as described previously [19] . The degree of left and right ventricular hypertrophy was determined by calculating the ratio of ventricular weight to tibial length, as tibial length represents a more appropriate correction for animal size than body weight in this model because administration of T, may be associated with a relative weight reduction [ 191.
RNA preparation
Total RNA was prepared from hearts using a modified version of the method described originally by Shields and Blobel [20] . Ventricular myocardial tissue was homogenized in 5 vols. of 0.15 mol/l NaCI, 0.05mol/l Tris (pH 8.3), 0.005mol/l EDTA and 1% (w/v) sodium dodecyl sulphate, using an Ultra-Turrax homogenizer. The homogenate was extracted twice with phenol/chloroform ( 1 : 1, v/v) and RNA was precipitated from the aqueous phase at -20°C by the addition of 2 vols. of ethanol and 0.1 vol. of 3 mol/l sodium acetate. The RNA pellet was resuspended in 5 0 0~1 of 0.001 mol/l EDTA, and RNA was reprecipitated by the addition of 2 vols. of 4.5 mol/l sodium acetate. RNA [pellet prepared by centrifugation ( 1 5 OOOg for 5 min, Eppendorf centrifuge)] was resuspended in 5 0 0~1 of 0.2mol/l potassium acetate and 0.005mol/l EDTA and was precipitated by the addition of ethanol at -20°C for 16 h. The final pellet was dissolved in 5 0 0~1 of sterile distilled water, and the concentration of RNA was calculated by measuring the absorbance of the sample at 260 nm. Typical yields were 0.75-1 mg of RNA/g of tissue.
Cytoplasmic dot hybridization
Levels of c-myc, c-fos and H-ras mRNAs in myocardial tissue were determined by dot hybridization to specific complementary DNA (cDNA) probes (c-myc, 5558 [21] ; c-fos, pc-fos 1 [22] ; H-ras, pH06T1 [23] ) and levels of p MHC mRNA were measured by hybridization to a specific oligonucleotide probe [24] using a method adapted from that reported by White and Bancroft [25] . Samples of myocardial RNA were denatured by heating to 60°C in 6 x SSC (0.9 mol/l NaCI, 0.09 mol/l trisodium citrate) and 8% (v/v) formaldehyde for 15 min. Forty microlitres of each cytoplasmic dilution (1WOpg of RNA) were applied in duplicate with suction to a nylon hybridization membrane held in a 96-well manifold. After dotting, the filters were allowed to dry, wrapped in Saran Wrap and fixed by irradiation with U.V. light for 5min.
Filters were prehybridized at 42°C for at least 2 h in buffer containing formamide and dextran sulphate, and hybridization was carried out in the same buffer for 18-20h as described previously [6] . Hybridization was detected by autoradiography for 6-72 h at -70"C, with intensifying screens, and quantified by scanning densitometry. The results of the densitometry were corrected for the amount of total mRNA applied in each dot determined by re- hybridization of each filter to radiolabelled oligodT. As the results obtained from the densitometry were relative rather than absolute values, the results were corrected so that controls equalled 1.00. There was a linear relationship between hybridization of the probe and the amount of RNA applied to the filter in dilution studies as demonstrated previously 
Statistical analysis
The statistical significance of the results was determined using Student's t-test for unpaired data. C6l.
Northern blot analysis RESULTS
RNA was prepared from the left and right ventricular myocardium of control and T,-treated rats (1, 3, 7 and 14 days T, treatment; n = 2 in each treatment group) by homogenization of ventricles in guanidinium isothiocyanate [26] and centrifugation through caesium chloride [27] . RNA samples were size-fractionated on a 1.5% formaldehyde agarose gel (301.18 per lane). To confirm that equal amounts of RNA were loaded in each track of the Northern blots, parallel samples were run on agarose minigels and stained with ethidium bromide. RNA was transferred to a nylon hybridization membrane by capillary blotting, and hybridized to labelled p MHC oligonucleotides as described above. Northern blot analysis confirmed hybridization of the /3 MHC oligonucleotide probe to a single species of mRNA (7.1 kb) in accordance with previous studies [5, 61 . Samples of myocardial RNA were hybridized in a similar manner to c-myc, c-fos and H-ras cDNAs. The specificity of hybridization of the proto-oncogene cDNAs employed was confirmed by Northern blot analysis which demonstrated hybridization of the myc, fos and ras cDNhs to single species of myocardial RNA of appropriate size [16, 28, 291 (Fig. 1) . After hybridization to /3 MHC and proto-oncogene probes, filters were re-probed with a synthetic oligonucleotide specific to a cardiac actin As expected, administration of T, was associated with a reduction in body weight (controls 207.8 _+ 1.6 g, 7 days T, treatment, 197.6f 3.6 g; means k SEM, P < 0.05 using Students t-test for unpaired data). An increase in weight of both the RV and LV and an increase in weight expressed as the ratio of ventricular weight to tibial length was apparent after 3 days of T, treatment and became more marked with increasing duration of T, administration (Table 1) . There was no significant difference in the relative hypertrophic response of the LV and RV to T, administration (percentage increase in ventricular weight corrected for tibial length after 14 days T, treatment compared with control: RV, 55.6 f 1.8%; LV, 60.8 f 2.9%; not significant).
The hypertrophic response of both ventricles to T, administration was associated with an increase in / 3 MHC mRNA in the RV, in the absence of a significant change in j MHC mRNA in the LV (Figs. 2 and 3) . The change in /? MHC mRNA in the RV increased with increasing duration of T, treatment, with significant differences from control animals evident by 3 days. In contrast with changes in /3 MHC mRNA in the RV, levels of a cardiac actin were unchanged (RV: control, 1.00+0.11; 1 day T, treatment, 1.19k0.12; 3 days T, treatment, 1.33f0.13; LV: control, l.OO_f0.14; 1 day T, treat- Changes in the levels of expression of protooncogene mRNAs were similarly confined to the RV. An increase in right ventricular concent rations of c-myc and c-fos mRNAs was seen with increasing duration of T, treatment with significant differences from controls evident by 7 and 14 days (Figs. 4 and  5) . In contrast, no change in right or left ventricular levels of H-ras mRNA was seen at any of the time points examined (RV: control, 1.00+0.19; 1 day T, treatment, 1.15k0.26; 3 days T, treatment, 1.56k 0.31; 7 days T, treatment, 1.05f0.23; 14 days T, treatment, 0.82 Ifi0.12 absorbance units/total mRNA; LV: control, l.OOt-0.19; 1 day T, treatment, 0.83k 0.13; 3 days T, treatment, 1.32+0.29; 7 days T, treatment, 0.83k0.14; 14 days T, treatment, 0.87k 0.09 absorbance units/total RNA; means f SEM, n = 6, not significant).
DISCUSSION
It is well established that thyroid hormone treatment leads to an increase in cardiac growth in a number of animal models and that this cardiac growth is due to a rapid increase in protein synthesis and myocyte cell size . In the present study we have confirmed that T, is a powerful stimulus for the induction of cardiac hypertrophy, both left and right ventricular weights being increased significantly after 3 days of T, treatment. The time period demonstrated for the development of hypertrophy agrees closely with a previous report using a similar dose regimen [33] , which demonstrated that heart weight was unaffected 18 or 48h after T, treatment (0.2 mg/kg) had begun, but was increased significantly after 72 h.
The present studies have revealed that although 14 days after beginning T, treatment both ventricles demonstrated a similar increase in weight, there were striking differences in mRNA expression in the RV and LV. Whilst induction of hypertrophy was not associated with significant changes in the levels There is considerable evidence implicating the products of specific proto-oncogenes, including cmyc, c-fos and H-ras, in the signal transduction of hypertrophic stimuli. Studies of induction of left ventricular hypertrophy by pressure overload have reported increases in left ventricular myc and ,fOs mRNAs occurring within an hour of acute pressure loading [16] , changes also observed at 10 days after imposition of the load [35] . A sustained increase in left ventricular H-ras mRNA after aortic constriction has also been reported [36] . It has been postulated, in view of the results of such studies of pressure overload, that one or more of these intracellular signals are essential prerequisites for stimulation of myocardial cell growth 112, 371. The observation that in the present study an increase in c-myc and c-fos mRNAs was confined to the RV, with no apparent stimulation in the LV, although both ventricles showed the same degree of hypertrophy, is compatible with the view that these proto-oncogene products are not essential for development of hypertrophy, although a role in the signal transduction process has not been entirely excluded since time points before 24 h were not examined. The present studies have not, however, addressed the cell specificity of expression of the proto-oncogenes examined: differences in left and right ventricular expression may reflect differences in cell-specific expression between the ventricles, rather than changes confined to the myocyte and thus implicated in controlling myocyte size.
Since the observed effect of T, treatment on B MHC gene expression in the present study argues against direct regulatory influences of T, on myocardial gene expression in this endocrine model of ventricular hypertrophy, other non-humoral stimuli of myocardial growth must be considered. It has been suggested that the hypertrophic response of the heart to T, may reflect the increase in heart rate induced by the administration of thyroid hormones; however, normalization of heart rate with propranolo1 in hyperthyroid rats has been reported to result in the same degree of hypertrophy as that found in rats receiving thyroid hormones alone [38] , suggesting that the development of hypertrophy is independent of changes in heart rate. The disparity between B MHC mRNAs in the RV and LV in the present study also argues against heart rate being the principal determinant of MHC gene expression. It is clear that enlargement of the heart due to excess thyroid hormone also leads to volume overload of both ventricles, but in contrast to the LV the RV is also subjected to a pressure overload. Zierhut and Zimmer [33j have shown that administration of T, (0.2 mg/kg daily for 72 h) caused only a slight (10%) increase in left ventricular systolic pressure but a more marked (34%) increase in right ventricular systolic pressure. These haemodynamic findings are in accord with the observation that in chronic hyperthyroidism the RV shows fibrosis and focal necrosis [39] (typical signs of chronic pressure overload), changes which are not observed in the LV. These findings also suggest that T,-induced hypertrophy reflects haemodynamic changes rather than a direct effect of thyroid hormones. This hypothesis is further supported by the findings of Klein and Hong [32] , who examined the effects of thyroid hormones on heterotransplanted rat hearts. In this study, cardiac transplantation into the abdominal cavity allowed a vascularly perfused, nonworking heart to be exposed to the same hormone levels as the beating heart in situ. Thyroid hormone administration resulted in a significant increase in the size and protein content of the heart in situ; however, these parameters were unaffected in the transplanted non-working heart, suggesting that thyroid hormone-induced cardiac hypertrophy is mediated by changes in cardiac work.
Studies of other experimental models of hypertrophy, such as coarctation of the aorta, have shown increases in /l MHC, c-my, c-fi~s and H-ras mRNAs in the pressure-overloaded LV [ 16, 28, 361 . Since the stimulus in such models for increased expression of the /? MHC and proto-oncogenes is pressure overload, perhaps in association with humoral stimuli such as an increase in circulating angiotensin 11, it is notable that in the present study changes in the expression of ,!3 MHC, myc and fos mRNAs were confined to the RV. The results of the haemodynamic studies of T, administration described above suggest that it is the right ventricular pressure overload induced by thyroid hormone administration which is responsible for the observed changes in right ventricular /3 MHC and protooncogene mRNAs induced by T, treatment.
